<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>PromptGenix – Specific Aims (1 page)</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <style>
    /* Print-friendly 1-page layout */
    @page { size: letter; margin: 0.75in; }
    body {
      font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Arial, sans-serif;
      color: #111827;
      line-height: 1.25;
      margin: 0;
      background: #ffffff;
    }
    .page {
      max-width: 8.5in;
      margin: 0 auto;
      padding: 0.75in;
    }
    h1 { font-size: 16pt; margin: 0 0 10px; }
    h2 { font-size: 11pt; margin: 14px 0 6px; text-transform: uppercase; letter-spacing: .06em; }
    p, li { font-size: 10.5pt; margin: 0 0 6px; }
    ul { margin: 6px 0 0 18px; padding: 0; }
    .meta { font-size: 9.5pt; color: #374151; margin-bottom: 10px; }
    .box {
      border: 1px solid #d1d5db;
      padding: 10px 12px;
      border-radius: 8px;
      margin-top: 8px;
      background: #f9fafb;
    }
    .small { font-size: 9.5pt; color: #374151; }
    .hr { height: 1px; background: #e5e7eb; margin: 10px 0; }
  </style>
</head>
<body>
  <div class="page">
    <h1>Specific Aims (Phase I): PromptGenix – BioAI Automation Platform</h1>
    <div class="meta">
      PromptGenix LLC (Women & Minority-Owned) • Contact: dohoon.kim1@icloud.com • Website: promptgenix.org/sbir.html
    </div>
    <div class="hr"></div>

    <h2>Significance</h2>
    <p>
      Immunology and infectious disease programs generate large volumes of RNA-Seq, scRNA-Seq, and high-dimensional
      flow cytometry data, yet analysis often depends on fragmented tools, custom scripts, and limited expert time.
      This drives long turnaround times, inconsistent reproducibility, and delayed biological interpretation.
    </p>

    <h2>Innovation</h2>
    <p>
      PromptGenix integrates end-to-end automated pipelines with an internal, literature-aware LLM layer that produces
      interpretable summaries and a <strong>Hypothesis Generator</strong> that ranks mechanistic hypotheses and proposes
      concrete validation experiments, grounded in PubMed-aware reasoning.
    </p>

    <h2>Overall Objective & Central Hypothesis</h2>
    <div class="box">
      <p>
        <strong>Objective:</strong> Deliver a validated, reproducible Phase I prototype that automates RNA-Seq and flow cytometry
        workflows and generates reviewer-ready reports with ranked hypotheses and follow-up experiments.
      </p>
      <p>
        <strong>Central hypothesis:</strong> Standardized automation combined with traceable, literature-aware LLM reasoning
        will reduce analysis turnaround time and increase interpretability, enabling faster, higher-quality study decisions
        in infectious disease and vaccine research.
      </p>
    </div>

    <h2>Specific Aims</h2>
    <ul>
      <li><strong>Aim 1:</strong> Harden end-to-end automated RNA-Seq and flow cytometry pipelines using public datasets (GEO/SRA/FlowRepository).</li>
      <li><strong>Aim 2:</strong> Implement a traceable Hypothesis Generator that ranks hypotheses and proposes validation experiments with PubMed-aware citations.</li>
      <li><strong>Aim 3:</strong> Generate exportable HTML/PDF reports and evaluate usability via 2–3 pilot partners using public or de-identified datasets.</li>
    </ul>

    <h2>Expected Outcomes & Deliverables</h2>
    <ul>
      <li>Validated prototype producing reproducible outputs across reruns (versioned configs + reports).</li>
      <li>Reviewer-ready reports generated within &lt;24 hours from raw data inputs.</li>
      <li>Measured improvements in turnaround time and user-rated usefulness of AI hypotheses.</li>
    </ul>

    <h2>Impact</h2>
    <p>
      Successful completion of Phase I will establish PromptGenix as a scalable BioAI co-investigator platform for
      immunology studies, enabling Phase II expansion to multi-site cohorts, secure deployments, and broader multi-omics integration.
    </p>

    <p class="small">
      Note: Phase I validation will use public datasets to avoid IP/data-use conflicts. Commercialization targets NIH-funded labs, government research groups, and CROs.
    </p>
  </div>
</body>
</html>
